author-photo

S. K. Anderson

Mayo Clinic

10

Papers

89

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) (Journal of Neuro-Oncology, (2019), 143, 3, (573-581), 10.1007/s11060-019-03194-z)

2019 Journal of Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (1)
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)

2019 Journal of Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (3)
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab

2016 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (44)
CLIN-NEURO/MEDICAL ONCOLOGY

2012 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (2)
NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study.

2011 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in patients (pts) with recurrent glioblastoma (rGBM) treated with bevacizumab (BEV) and sorafenib (SOR).

2011 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (BEV) and sorafenib.

2011 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM.

2010 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)